IceCure Medical to Slash Share Count by 96.7% in One-for-30 Reverse Split
ICCM•IceCure Medical will implement a one-for-thirty reverse share split effective June 4 to boost its per-share price and comply with Nasdaq’s $1 bid requirement. The split shrinks outstanding shares from 84.2 million to about 2.8 million and triggers proportional adjustments to options, warrants and RSUs with fractional shares rounded per corporate rules.
1. Reverse Split Details
The board approved and will implement a one-for-thirty reverse share split effective June 4, 2026, consolidating the company’s ordinary shares and issuing new shares under CUSIP M53071201. Outstanding shares will decrease from 84,201,034 to approximately 2,806,701.
2. Shareholder Impact and Equity Adjustments
All shareholders experience the split uniformly, with fractional shares rounded under the company’s articles of association. Ordinary shares underlying options, warrants, restricted shares and share incentive plans will be proportionally adjusted, increasing per-share exercise prices accordingly.
3. Nasdaq Compliance Timeline and Strategy
The reverse split aims to raise the per-share trading price above Nasdaq’s $1.00 minimum bid requirement, with the company granted until November 9, 2026 to regain compliance. Shareholders approved the split at a special meeting on May 11, 2026, as part of a broader capital markets strategy to maintain Nasdaq listing.
